MedTrace Logo

Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy

NCT06090994 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 756

Last updated 2025-05-07

No results posted yet for this study

Summary

This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer

Conditions

Interventions

DRUG

Huaier granule

Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.

DRUG

Capecitabine

Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Sanjun Cai, PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-18
Primary Completion
2027-07-31
Completion
2029-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06090994 on ClinicalTrials.gov